[24].Pommier Y, Oconnor M J, De Bono J S, et al. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action[J]. Science Translational Medicine, 2016, 8(362).DOI:10.1126/scitranslmed.aaf9246 [25].Sun K, Mikule K, Wang Z, et al. A comparative pharmacokin...
Various molecular mechanisms of the acquired resistance have been clarified. This chapter describes the synthetic lethal mechanism of PARP inhibitors, the mechanism of acquired resistance to PARP inhibitors, and the development of various PARP inhibitors.Sunada, Shigeaki...
[24].Pommier Y, Oconnor M J, De Bono J S, et al. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action[J]. Science Translational Medicine, 2016, 8(362).DOI:10.1126/scitranslmed.aaf9246 [25].Sun K, Mikule K, Wang Z, et al. A comparative pharmacokin...
[6].Peraltaleal A, Rodriguezvargas J M, Aguilarquesada R, et al. PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases[J]. Free Radical Biology and Medicine, 2009, 47(1): 13-26.DOI:10.1016/j.freeradbiomed.2009.04.008 [7].Langelier M, Riccio A A, Pascal J...
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action[J]. Science Translational Medicine, 2016, 8(362). DOI:10.1126/scitranslmed.aaf9246 【20】Ghosh R, Roy S, Kamyab J, et al. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 ...
The mechanism of action of PARP inhibitors is to inhibit the DNA repair enzyme PARP, prevent the formation of “multi-ADP-ribose” (poly), and prevent the normal aggregation of DNA molecules. The mechanism of action of PARP inhibitors is divided into three steps: first, according to the ...
This review summarizes current insights into the mechanism of action ofPARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class ofanti-cancer drugs.Keywords: Poly (ADP-ribose) polymerases, Nicotinamide, RucaparibFindingsPoly (ADP-ribose) ...
Mechanism of Action Resource Library HCP Resources Patient Resources ProstateHRRm* orBRCAm* MetastaticCastration-Resistant Home Efficacy Combination Therapy inBRCAm* mCRPC Monotherapy in HRRm* mCRPC HRR/BRCATesting Dosing & Management Safety & Tolerability ...
This review mainly introduces the concept of synthetic lethality and homologous recombination, describes the mechanism of action of PARP inhibitors within this concept, discusses problems such as resistance, enumerates the current progress and achievements of clinical trials for PARP inhibitors in pancreatic...
Mechanism PARP inhibitors (PARPi) are oral-targeted therapies, which competitively bind to the NAD + sites of PARP1 and PARP2 inducing a catalytic inhibition (Fig.2a, b). Five different molecules are currently under development or recently approved: olaparib, rucaparib, niraparib, veliparib...